Multivalent influenza nanoparticle vaccines
Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.
1. A composition comprising:
(i) a first HaSMaN (Hemagglutinin Saponin Matrix Nanoparticle) comprising:
(a) a first ISCOM matrix particle comprising Fraction A of Quillaja Saponaria Molina and not Fraction C of Quillaja Saponaria Molina, and
(b) a first recombinant influenza hemagglutinin (HA) glycoprotein trimer, wherein the HA glycoprotein tail is associated with the first ISCOM matrix particle and wherein the HA glycoprotein head extends distally from the first ISCOM matrix particle;
(ii) a second HaSMaN comprising:
(a) a second ISCOM matrix particle comprising Fraction C of Quillaja Saponaria Molina and not Fraction A of Quillaja Saponaria Molina, and
(b) a second recombinant influenza HA glycoprotein trimer, wherein the HA glycoprotein tail is associated with the second ISCOM matrix particle and wherein the HA glycoprotein head extends distally from the second ISCOM matrix particle; and
(iii) a pharmaceutically acceptable buffer or carrier;
wherein each of the first and the second HA glycoprotein is from a Type A influenza strain, and
wherein each of the first and the second HA glycoprotein contains a transmembrane domain.
2. The composition of claim 1 , wherein the Type A influenza strain is of a subtype selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.
3. A method of preparing a HaSMaN comprising combining a detergent core nanoparticle containing hemagglutinin (HA) with an ISCOM matrix particle for at least about four hours,
wherein the ISCOM matrix particle comprises Fraction A of Quillaja Saponaria Molina and not Fraction C of Quillaja Saponaria Molina;
wherein the HA contains a transmembrane domain, and
wherein the HA is from a Type A influenza strain.
4. The method of claim 3 , wherein the detergent is PS80.
5. The method of claim 3 , comprising combining the detergent core nanoparticle with the ISCOM matrix particle at a temperature of about 25° C. for at least about 24 hours.
6. The method of claim 3 , wherein the Type A influenza strain is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.
7. A method of stimulating an immune response against influenza comprising administering the composition of claim 1 .
8. The method of claim 7 , wherein the composition is administered intramuscularly.
9. A method of preparing a HaSMaN comprising combining a detergent core nanoparticle containing hemagglutinin (HA) with an ISCOM matrix particle for at least about four hours,
wherein the ISCOM matrix particle comprises Fraction C of Quillaja Saponaria Molina and not Fraction A of Quillaja Saponaria Molina;
wherein the HA contains a transmembrane domain, and
wherein the HA is from a Type A influenza strain.
10. The method of claim 9 , wherein the detergent is PS80.
11. The method of claim 9 , comprising combining the detergent core nanoparticle with the ISCOM matrix particle at a temperature of about 25° C. for at least about 24 hours.
12. The method of claim 9 , wherein the Type A influenza strain is selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and H18.